The impact of PBRM1 mutations on overall survival in greater than 2,100 patients treated with immune checkpoint blockade (ICB).

A. Ari Hakimi,Yasser Ged,Jessica Flynn,Douglas R Hoen,Renzo G. Di Natale,Kyle A. Blum,Vladimir Makarov,Fengshen Kuo,Maria I. Carlo,Chung-Han Lee,Martin H. Voss,Irina Ostrovnaya,Timothy A. Chan,Robert J. Motzer

The impact of PBRM1 mutations on overall survival in greater than 2,100 patients treated with immune checkpoint blockade (ICB).

2019

A. Ari Hakimi
Yasser Ged
Jessica Flynn
Douglas R Hoen
Renzo G. Di Natale
Kyle A. Blum
Vladimir Makarov
Fengshen Kuo
Maria I. Carlo
Chung-Han Lee
Martin H. Voss
Irina Ostrovnaya
Timothy A. Chan
Robert J. Motzer

666Background: PBRM1 is the second most commonly mutated gene in clear cell renal cell carcinoma (ccRCC). We have previously shown favorable outcomes in PBRM1-mutated ccRCC tumors treated with vasc...

Keywords:

Oncology
Pathology
Blockade
Immune checkpoint
Internal medicine
Medicine
PBRM1
overall survival
Cancer research
Gene
Clear cell renal cell carcinoma

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations